CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RNF115 (ImmuneEditome ID:27246)

1. Gene summary of enriched editing regions for RNF115

check button Gene summary
Gene informationGene symbol

RNF115

Gene ID

27246

GeneSynonymsBCA2|RABRING7|ZFP364|ZNF364
GeneCytomap

1q21.1

GeneTypeprotein-coding
GeneDescriptionE3 ubiquitin-protein ligase RNF115|RING-type E3 ubiquitin transferase RNF115|rab7-interacting RING finger protein|rabring 7|zinc finger protein 364
GeneModificationdate20230329
UniprotIDQ9Y4L5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:145739821-145742076:-ENST00000582693.4ENSG00000265491.4RNF115UTR3AluSz6,Charlie23a,MIRc,AluSzchr1:145739821-145742076:-.alignment
chr1:145745194-145746213:-ENST00000582693.4ENSG00000265491.4RNF115UTR3AluJb,AluSq,AluSc8chr1:145745194-145746213:-.alignment
chr1:145756947-145757112:-ENST00000539368.2ENSG00000265491.4RNF115ncRNA_intronicAluSxchr1:145756947-145757112:-.alignment
chr1:145774398-145776802:-ENST00000582693.4ENSG00000265491.4RNF115intronicAluSx1,L1M5,AluSq2,AluSz,MER44A,AluSx3,AluJrchr1:145774398-145776802:-.alignment
chr1:145781950-145783120:-ENST00000582693.4ENSG00000265491.4RNF115intronicAluSq,FLAM_A,AluSxchr1:145781950-145783120:-.alignment
chr1:145789514-145789940:-ENST00000582693.4ENSG00000265491.4RNF115intronicAluSx1,AluSpchr1:145789514-145789940:-.alignment
chr1:145793067-145794160:-ENST00000582693.4ENSG00000265491.4RNF115intronicAluSz,L2a,AluJochr1:145793067-145794160:-.alignment
chr1:145809230-145809472:-ENST00000582693.4ENSG00000265491.4RNF115intronicAluSxchr1:145809230-145809472:-.alignment


Top

2. Tumor-specific enriched editing regions for RNF115


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:145745194-145746213:-BRCAEER8.1164e-06image
ENSG00000265491.4,RNF115BRCAEAG6.3523e-06image
chr1:145745194-145746213:-HNSCEER5.3386e-10image
ENSG00000265491.4,RNF115HNSCEAG5.2975e-10image
chr1:145745194-145746213:-KIRPEER4.5133e-04image
ENSG00000265491.4,RNF115KIRPEAG5.5861e-04image
chr1:145745194-145746213:-LUSCEER1.1538e-02image
ENSG00000265491.4,RNF115LUSCEAG1.0508e-02image
chr1:145745194-145746213:-STADEER1.5131e-03image
ENSG00000265491.4,RNF115STADEAG9.0115e-04image
chr1:145745194-145746213:-THCAEER6.8911e-04image
ENSG00000265491.4,RNF115THCAEAG7.7207e-04image
chr1:145745194-145746213:-UCECEER2.1303e-05image
ENSG00000265491.4,RNF115UCECEAG3.3933e-05image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000265491.4,RNF115KIRCPathEAG3.4163e-022.6333e-020.0966image
ENSG00000265491.4,RNF115READPathEAG4.8033e-029.4169e-03-0.2128image
chr1:145745194-145746213:-READPathEER4.8033e-029.4169e-03-0.2128image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr1:145745194-145746213:-KIRPEER3.8044e-024.5280e-031.8071e-05image
ENSG00000265491.4,RNF115KIRPEAG1.0131e-024.2781e-031.5229e-05image
chr1:145745194-145746213:-LIHCEER1.9031e-029.1290e-031.7978e-02image
ENSG00000265491.4,RNF115LIHCEAG1.9031e-029.9713e-032.3401e-02image
chr1:145745194-145746213:-LUSCEER2.9526e-023.3204e-032.5324e+01image
ENSG00000265491.4,RNF115LUSCEAG2.6449e-023.1415e-032.5820e+01image
chr1:145745194-145746213:-UCECEER1.8400e-034.1347e-026.9232e+01image
ENSG00000265491.4,RNF115UCECEAG1.6599e-033.9802e-026.6131e+01image

Top

3. Enriched editing regions and immune related genes for RNF115


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:145745194-145746213:-KIRPEERENSG00000267673,FDX1L0.30651.7065e-058.3418e-130.4091imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_ANDROGEN_RESPONSE
chr1:145745194-145746213:-KIRPEERENSG00000140365,COMMD40.28597.5831e-052.6328e-120.4008imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAT_cells_gamma_deltaGSVA_HALLMARK_UV_RESPONSE_DN
chr1:145745194-145746213:-DLBCEERENSG00000228223,HCG11-0.56031.6360e-022.7007e-03-0.4322imageNFBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56HCG11B_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:145745194-145746213:-DLBCEERENSG00000168395,ING5-0.59181.8454e-024.4665e-04-0.4967imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAMast_cells_activatedGSVA_HALLMARK_P53_PATHWAY
chr1:145745194-145746213:-DLBCEERENSG00000137413,TAF8-0.57622.4197e-022.9892e-04-0.5095imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56TAF8B_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:145745194-145746213:-DLBCEERENSG00000105323,HNRNPUL1-0.56072.9423e-021.7449e-03-0.4491imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAMacrophages_M2GSVA_HALLMARK_MITOTIC_SPINDLE
chr1:145745194-145746213:-DLBCEERENSG00000100023,PPIL2-0.55073.0810e-026.4964e-04-0.4842imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56PPIL2B_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:145745194-145746213:-DLBCEERENSG00000249115,HAUS5-0.51783.1290e-027.1786e-04-0.4809imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAB_cells_naiveGSVA_HALLMARK_G2M_CHECKPOINT
chr1:145745194-145746213:-DLBCEERENSG00000165512,ZNF22-0.55433.2873e-021.6818e-04-0.5270imageNFBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NANK_cells_restingGSVA_HALLMARK_G2M_CHECKPOINT
chr1:145745194-145746213:-DLBCEERENSG00000231365,RP11-418J17.1-0.53253.3521e-028.2862e-04-0.4759imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAMast_cells_activatedGSVA_HALLMARK_G2M_CHECKPOINT

More results



Top

4. Enriched editing regions and immune related splicing for RNF115


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000265491.4,RNF115
HNSCEAGMEXENSG00000138071.9chr265239851:65239962:65242048:65242063:65246184:65246307:65246523:65246718-0.28013.4933e-123.0617e-16-0.4076imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAPlasma_cellsGSVA_HALLMARK_MYOGENESIS
chr1:145745194-145746213:-
HNSCEERMEXENSG00000138071.9chr265239851:65239962:65242045:65242063:65246184:65246307:65246523:65246718-0.25729.6859e-124.4628e-16-0.4091imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAMast_cells_restingGSVA_HALLMARK_MYOGENESIS
chr1:145745194-145746213:-
HNSCEERMEXENSG00000138071.9chr265239851:65239962:65242048:65242063:65246184:65246307:65246523:65246718-0.27539.8955e-128.1438e-17-0.4153imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAPlasma_cellsGSVA_HALLMARK_MYOGENESIS
ENSG00000265491.4,RNF115
PCPGEAGIRENSG00000099821.9chr19622534:622985:623453:6236030.35371.7078e-034.3992e-100.4530imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NANK_cells_activatedGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
chr1:145745194-145746213:-
PCPGEERIRENSG00000099821.9chr19622534:622985:623453:6236030.35651.7621e-034.8385e-100.4520imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NANK_cells_activatedGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
chr1:145745194-145746213:-
STADEERMEXENSG00000110700.2chr1117075096:17075197:17075453:17075546:17075588:17075623:17077167:170772460.40933.2861e-123.6327e-160.4107imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr1:145745194-145746213:-
STADEERMEXENSG00000110700.2chr1117075096:17075197:17075453:17075491:17075588:17075623:17077167:170772460.40943.2893e-123.6105e-160.4108imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000265491.4,RNF115
STADEAGMEXENSG00000164896.15chr7151078561:151078701:151078841:151078980:151079680:151079922:151080684:151080842-0.38223.0414e-101.4182e-15-0.4021imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184FASTKT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr1:145745194-145746213:-
STADEERMEXENSG00000092841.14chr1256158683:56158711:56159586:56159622:56159622:56159730:56159974:561599870.38461.6900e-106.5726e-160.4074imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr1:145745194-145746213:-
STADEERMEXENSG00000110700.2chr1117075096:17075197:17075453:17075572:17075588:17075623:17077167:170772460.40635.3412e-126.9489e-160.4071imageNAUH;FBL;FUS;HNRNPA1;HNRNPC;HNRNPM;NOP56NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION

More results



Top

5. Enriched editing regions and immune infiltration for RNF115


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:145745194-145746213:-BLCAEERDendritic_cells_resting3.9322e-030.1442image
ENSG00000265491.4,RNF115BLCAEAGDendritic_cells_resting4.0064e-030.1438image
chr1:145745194-145746213:-BRCAEERNK_cells_activated3.2419e-070.1548image
chr1:145774398-145776802:-BRCAEERNK_cells_resting1.4933e-020.3182image
chr1:145793067-145794160:-BRCAEEREosinophils5.0719e-030.2324image
ENSG00000265491.4,RNF115BRCAEAGNK_cells_activated1.1373e-060.1473image
chr1:145745194-145746213:-CHOLEERMacrophages_M04.6233e-020.3392image
ENSG00000265491.4,RNF115CHOLEAGMacrophages_M04.6222e-020.3392image
chr1:145745194-145746213:-COADEERNK_cells_activated1.0021e-020.1574image
ENSG00000265491.4,RNF115COADEAGDendritic_cells_activated9.0386e-040.1998image
chr1:145745194-145746213:-DLBCEERB_cells_naive1.7901e-02-0.3477image
ENSG00000265491.4,RNF115DLBCEAGB_cells_naive1.8464e-02-0.3461image
chr1:145781950-145783120:-ESCAEERNK_cells_resting3.5990e-020.3101image
chr1:145745194-145746213:-GBMEERPlasma_cells1.2938e-020.1926image
ENSG00000265491.4,RNF115GBMEAGPlasma_cells1.3428e-020.1916image
chr1:145745194-145746213:-HNSCEERMast_cells_resting2.5779e-03-0.1370image
ENSG00000265491.4,RNF115HNSCEAGMast_cells_resting2.0171e-03-0.1402image
chr1:145745194-145746213:-KICHEERT_cells_CD4_memory_activated9.7825e-030.3182image
ENSG00000265491.4,RNF115KICHEAGT_cells_CD4_memory_activated1.3200e-020.3059image
chr1:145745194-145746213:-KIRCEERT_cells_regulatory_(Tregs)1.7189e-040.1916image
chr1:145793067-145794160:-KIRCEERNK_cells_resting3.6931e-030.5693image
ENSG00000265491.4,RNF115KIRCEAGNK_cells_activated6.3526e-050.2032image
chr1:145745194-145746213:-LAMLEERNeutrophils2.2359e-020.1980image
chr1:145781950-145783120:-LAMLEERT_cells_CD4_memory_activated8.8443e-030.2730image
ENSG00000265491.4,RNF115LAMLEAGT_cells_CD4_memory_activated1.9048e-020.1932image
chr1:145739821-145742076:-LGGEERNK_cells_resting8.4081e-040.2915image
chr1:145745194-145746213:-LGGEERT_cells_CD4_memory_resting3.4291e-03-0.1271image
ENSG00000265491.4,RNF115LGGEAGT_cells_CD4_memory_resting2.3159e-03-0.1323image
chr1:145745194-145746213:-LUADEERB_cells_memory4.2352e-030.1268image
ENSG00000265491.4,RNF115LUADEAGT_cells_CD4_naive2.2258e-03-0.1343image
chr1:145745194-145746213:-LUSCEERT_cells_regulatory_(Tregs)5.7740e-030.1238image
ENSG00000265491.4,RNF115LUSCEAGT_cells_regulatory_(Tregs)5.6096e-030.1242image
chr1:145745194-145746213:-MESOEERMonocytes2.8674e-020.2447image
ENSG00000265491.4,RNF115MESOEAGMonocytes2.8738e-020.2446image
chr1:145745194-145746213:-OVEERPlasma_cells2.4902e-020.1315image
chr1:145774398-145776802:-OVEERMacrophages_M12.6026e-020.2272image
chr1:145781950-145783120:-OVEERPlasma_cells2.5638e-040.7303image
ENSG00000265491.4,RNF115OVEAGT_cells_regulatory_(Tregs)1.2598e-020.1461image
chr1:145745194-145746213:-PAADEERMast_cells_activated3.7850e-030.2184image
ENSG00000265491.4,RNF115PAADEAGMast_cells_activated3.7737e-030.2185image
chr1:145745194-145746213:-PCPGEERT_cells_follicular_helper1.7792e-020.1795image
ENSG00000265491.4,RNF115PCPGEAGT_cells_follicular_helper1.3642e-020.1862image
chr1:145745194-145746213:-PRADEERT_cells_gamma_delta4.3993e-03-0.1274image
chr1:145793067-145794160:-PRADEERMonocytes2.1431e-03-0.3951image
ENSG00000265491.4,RNF115PRADEAGT_cells_gamma_delta4.6455e-03-0.1267image
chr1:145745194-145746213:-READEERT_cells_regulatory_(Tregs)3.3015e-030.3000image
ENSG00000265491.4,RNF115READEAGT_cells_regulatory_(Tregs)3.3015e-030.3000image
chr1:145745194-145746213:-SARCEERB_cells_memory1.2658e-02-0.1566image
ENSG00000265491.4,RNF115SARCEAGB_cells_memory2.3358e-02-0.1423image
chr1:145745194-145746213:-SKCMEERMast_cells_activated8.4779e-03-0.1216image
ENSG00000265491.4,RNF115SKCMEAGMast_cells_activated9.2728e-03-0.1201image
chr1:145739821-145742076:-STADEERMacrophages_M21.2744e-030.4703image
chr1:145745194-145746213:-STADEERT_cells_regulatory_(Tregs)1.0638e-050.2292image
chr1:145774398-145776802:-STADEERMonocytes2.5988e-03-0.2309image
chr1:145781950-145783120:-STADEERT_cells_regulatory_(Tregs)1.7082e-02-0.2240image
chr1:145793067-145794160:-STADEERMast_cells_resting1.8622e-02-0.1589image
ENSG00000265491.4,RNF115STADEAGT_cells_regulatory_(Tregs)1.3395e-030.1675image
chr1:145745194-145746213:-TGCTEERMonocytes1.1384e-020.2054image
ENSG00000265491.4,RNF115TGCTEAGMonocytes1.2152e-020.2036image
chr1:145745194-145746213:-THYMEERT_cells_regulatory_(Tregs)1.4170e-02-0.2323image
chr1:145745194-145746213:-UCECEERT_cells_regulatory_(Tregs)1.5845e-020.1870image
ENSG00000265491.4,RNF115UCECEAGT_cells_CD4_memory_resting4.3851e-03-0.2169image
chr1:145745194-145746213:-UCSEERMacrophages_M02.0464e-020.3091image
ENSG00000265491.4,RNF115UCSEAGMacrophages_M02.1194e-020.3074image


Top

6. Enriched editing regions and immune gene sets for RNF115


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr1:145745194-145746213:-PCPGEER2.3422e-02-0.17183.4794e-02-0.16012.0091e-02-0.17615.8069e-03-0.2083image
chr1:145774398-145776802:-STADEER7.7882e-030.20472.3339e-020.17494.7451e-030.21693.6496e-030.2231image
chr1:145781950-145783120:-STADEER1.0694e-030.30384.0768e-020.19288.1555e-030.24772.2067e-020.2152image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000265491.4,RNF115ACCGSVA_HALLMARK_NOTCH_SIGNALINGEAG1.5703e-02-0.2745image
chr1:145745194-145746213:-ACCGSVA_HALLMARK_NOTCH_SIGNALINGEER1.5703e-02-0.2745image
ENSG00000265491.4,RNF115BLCAGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.8713e-04-0.1693image
chr1:145745194-145746213:-BLCAGSVA_HALLMARK_HEME_METABOLISMEER7.2528e-04-0.1687image
ENSG00000265491.4,RNF115BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG7.3812e-10-0.1858image
chr1:145745194-145746213:-BRCAGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.7517e-10-0.1927image
chr1:145774398-145776802:-BRCAGSVA_HALLMARK_APICAL_SURFACEEER3.2502e-030.3801image
chr1:145793067-145794160:-BRCAGSVA_HALLMARK_MITOTIC_SPINDLEEER3.4619e-02-0.1762image
chr1:145745194-145746213:-CESCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.7727e-04-0.2163image
ENSG00000265491.4,RNF115CESCGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.0225e-04-0.2082image
chr1:145745194-145746213:-CHOLGSVA_HALLMARK_MYC_TARGETS_V2EER6.2619e-030.4532image
ENSG00000265491.4,RNF115CHOLGSVA_HALLMARK_MYC_TARGETS_V2EAG6.5502e-030.4510image
chr1:145745194-145746213:-COADGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.4869e-02-0.1373image
ENSG00000265491.4,RNF115COADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.4747e-03-0.1825image
ENSG00000265491.4,RNF115DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.3637e-020.3613image
chr1:145745194-145746213:-DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.2980e-020.3637image
chr1:145745194-145746213:-ESCAGSVA_HALLMARK_PEROXISOMEEER1.3473e-02-0.1950image
chr1:145781950-145783120:-ESCAGSVA_HALLMARK_PEROXISOMEEER4.0454e-02-0.3033image
ENSG00000265491.4,RNF115GBMGSVA_HALLMARK_NOTCH_SIGNALINGEAG3.3779e-02-0.1649image
chr1:145745194-145746213:-GBMGSVA_HALLMARK_NOTCH_SIGNALINGEER3.9371e-02-0.1601image
chr1:145745194-145746213:-HNSCGSVA_HALLMARK_MYOGENESISEER5.1447e-10-0.2782image
ENSG00000265491.4,RNF115HNSCGSVA_HALLMARK_MYOGENESISEAG4.0260e-10-0.2795image
chr1:145745194-145746213:-KICHGSVA_HALLMARK_ANDROGEN_RESPONSEEER8.1319e-03-0.3256image
ENSG00000265491.4,RNF115KICHGSVA_HALLMARK_ANDROGEN_RESPONSEEAG5.1732e-03-0.3429image
ENSG00000265491.4,RNF115KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG7.6858e-060.2266image
chr1:145745194-145746213:-KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.1820e-050.2159image
ENSG00000265491.4,RNF115KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.0156e-05-0.2595image
chr1:145745194-145746213:-KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER9.8410e-06-0.2599image
chr1:145774398-145776802:-LAMLGSVA_HALLMARK_APICAL_SURFACEEER1.5730e-020.2278image
ENSG00000265491.4,RNF115LAMLGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.4066e-030.2610image
chr1:145781950-145783120:-LAMLGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.3334e-050.4278image
chr1:145745194-145746213:-LAMLGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.5507e-02-0.1825image
ENSG00000265491.4,RNF115LGGGSVA_HALLMARK_PROTEIN_SECRETIONEAG4.1505e-08-0.2359image
chr1:145745194-145746213:-LGGGSVA_HALLMARK_PROTEIN_SECRETIONEER2.3561e-08-0.2400image
ENSG00000265491.4,RNF115LIHCGSVA_HALLMARK_HEME_METABOLISMEAG4.1566e-03-0.1520image
chr1:145745194-145746213:-LIHCGSVA_HALLMARK_HEME_METABOLISMEER6.7260e-03-0.1438image
ENSG00000265491.4,RNF115LUADGSVA_HALLMARK_P53_PATHWAYEAG8.1886e-040.1469image
chr1:145745194-145746213:-LUADGSVA_HALLMARK_P53_PATHWAYEER2.0188e-020.1031image
chr1:145745194-145746213:-LUSCGSVA_HALLMARK_PROTEIN_SECRETIONEER1.2639e-04-0.1713image
ENSG00000265491.4,RNF115LUSCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.0909e-04-0.1729image
chr1:145745194-145746213:-MESOGSVA_HALLMARK_HEME_METABOLISMEER9.5940e-03-0.2880image
ENSG00000265491.4,RNF115MESOGSVA_HALLMARK_HEME_METABOLISMEAG9.3170e-03-0.2890image
chr1:145774398-145776802:-OVGSVA_HALLMARK_PEROXISOMEEER7.5199e-030.2712image
chr1:145745194-145746213:-OVGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.4455e-030.1859image
ENSG00000265491.4,RNF115OVGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.3228e-040.2222image
chr1:145781950-145783120:-OVGSVA_HALLMARK_BILE_ACID_METABOLISMEER1.9532e-020.5172image
ENSG00000265491.4,RNF115PCPGGSVA_HALLMARK_UV_RESPONSE_DNEAG2.2806e-05-0.3143image
chr1:145745194-145746213:-PCPGGSVA_HALLMARK_UV_RESPONSE_DNEER3.5937e-06-0.3430image
chr1:145793067-145794160:-PRADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER1.9221e-03-0.3989image
ENSG00000265491.4,RNF115PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.0824e-03-0.1460image
chr1:145745194-145746213:-PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.0312e-03-0.1380image
chr1:145745194-145746213:-READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.7381e-020.2051image
ENSG00000265491.4,RNF115READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.7381e-020.2051image
chr1:145745194-145746213:-SARCGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.4329e-020.1331image
ENSG00000265491.4,RNF115SARCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.5970e-020.1397image
chr1:145793067-145794160:-SKCMGSVA_HALLMARK_APICAL_SURFACEEER3.2093e-020.4479image
chr1:145745194-145746213:-SKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.7562e-06-0.2188image
ENSG00000265491.4,RNF115SKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.7319e-06-0.2190image
ENSG00000265491.4,RNF115STADGSVA_HALLMARK_KRAS_SIGNALING_DNEAG3.5952e-070.2629image
chr1:145781950-145783120:-STADGSVA_HALLMARK_GLYCOLYSISEER1.5937e-030.2937image
chr1:145793067-145794160:-STADGSVA_HALLMARK_P53_PATHWAYEER1.5058e-050.2879image
chr1:145745194-145746213:-STADGSVA_HALLMARK_PROTEIN_SECRETIONEER9.4176e-09-0.2960image
chr1:145774398-145776802:-STADGSVA_HALLMARK_GLYCOLYSISEER2.3760e-040.2799image
ENSG00000265491.4,RNF115TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.2201e-04-0.3076image
chr1:145745194-145746213:-TGCTGSVA_HALLMARK_MITOTIC_SPINDLEEER1.3149e-04-0.3062image
ENSG00000265491.4,RNF115THCAGSVA_HALLMARK_UV_RESPONSE_DNEAG7.7137e-04-0.1496image
chr1:145745194-145746213:-THCAGSVA_HALLMARK_UV_RESPONSE_DNEER3.2481e-04-0.1601image
ENSG00000265491.4,RNF115THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.7969e-03-0.2714image
chr1:145745194-145746213:-THYMGSVA_HALLMARK_E2F_TARGETSEER8.9456e-03-0.2471image
chr1:145745194-145746213:-UCECGSVA_HALLMARK_PROTEIN_SECRETIONEER1.1520e-03-0.2502image
ENSG00000265491.4,RNF115UCECGSVA_HALLMARK_MITOTIC_SPINDLEEAG5.0299e-03-0.2136image
ENSG00000265491.4,RNF115UCSGSVA_HALLMARK_MYOGENESISEAG1.4697e-03-0.4150image
chr1:145745194-145746213:-UCSGSVA_HALLMARK_MYOGENESISEER1.4133e-03-0.4164image
ENSG00000265491.4,RNF115UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEAG2.8969e-050.4573image
chr1:145745194-145746213:-UVMGSVA_HALLMARK_KRAS_SIGNALING_DNEER2.8969e-050.4573image


Top

7. Enriched editing regions and drugs for RNF115


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr1:145745194-145746213:-ACCBAY.61.3606EER2.3034e-040.4080image
ENSG00000265491.4,RNF115ACCBAY.61.3606EAG2.3034e-040.4080image
ENSG00000265491.4,RNF115BLCAAZD6482EAG5.6072e-040.1720image
chr1:145745194-145746213:-BLCAEmbelinEER7.9374e-040.1675image
chr1:145774398-145776802:-BRCAABT.263EER5.5740e-030.3595image
chr1:145793067-145794160:-BRCAGSK269962AEER2.0103e-03-0.2553image
ENSG00000265491.4,RNF115BRCAGW843682XEAG2.1409e-09-0.1807image
chr1:145745194-145746213:-BRCAGW843682XEER1.3531e-09-0.1832image
chr1:145745194-145746213:-CESCBMS.509744EER7.4952e-06-0.2570image
ENSG00000265491.4,RNF115CESCBMS.509744EAG1.9981e-05-0.2447image
chr1:145745194-145746213:-CHOLDocetaxelEER4.6105e-03-0.4677image
ENSG00000265491.4,RNF115CHOLDocetaxelEAG4.8002e-03-0.4658image
ENSG00000265491.4,RNF115COADBMS.509744EAG3.4534e-030.1764image
chr1:145745194-145746213:-COADMethotrexateEER1.6807e-020.1462image
chr1:145745194-145746213:-DLBCAZ628EER3.1670e-02-0.3173image
ENSG00000265491.4,RNF115DLBCAZ628EAG3.3538e-02-0.3141image
ENSG00000265491.4,RNF115GBMFTI.277EAG1.7240e-020.1846image
chr1:145745194-145746213:-GBMFTI.277EER1.5003e-020.1885image
ENSG00000265491.4,RNF115HNSCGNF.2EAG5.0147e-060.2066image
chr1:145745194-145746213:-HNSCGNF.2EER4.9002e-060.2068image
ENSG00000265491.4,RNF115KICHAZD.2281EAG2.2855e-03-0.3719image
chr1:145745194-145746213:-KICHAZD.2281EER2.2425e-03-0.3725image
ENSG00000265491.4,RNF115KIRCEmbelinEAG1.1696e-070.2670image
chr1:145745194-145746213:-KIRCBMS.536924EER2.2796e-07-0.2624image
chr1:145793067-145794160:-KIRCJNJ.26854165EER3.3237e-03-0.5745image
ENSG00000265491.4,RNF115KIRPEmbelinEAG2.2268e-060.2774image
chr1:145745194-145746213:-KIRPEmbelinEER2.6271e-070.3008image
chr1:145774398-145776802:-LAMLLFM.A13EER3.3282e-02-0.2013image
chr1:145745194-145746213:-LAMLDocetaxelEER6.2400e-030.2360image
chr1:145781950-145783120:-LAMLCI.1040EER3.8375e-03-0.3002image
ENSG00000265491.4,RNF115LAMLJNK.9LEAG8.4041e-03-0.2166image
ENSG00000265491.4,RNF115LGGBIRB.0796EAG3.8068e-04-0.1541image
chr1:145745194-145746213:-LGGCisplatinEER3.1201e-040.1563image
chr1:145739821-145742076:-LGGLFM.A13EER3.1541e-020.1902image
ENSG00000265491.4,RNF115LIHCCyclopamineEAG1.2924e-02-0.1357image
chr1:145745194-145746213:-LIHCCyclopamineEER1.1191e-02-0.1384image
chr1:145745194-145746213:-LUADAZD6244EER3.1518e-03-0.1310image
ENSG00000265491.4,RNF115LUADBMS.536924EAG1.2490e-03-0.1424image
chr1:145745194-145746213:-LUSCBosutinibEER1.5420e-03-0.1418image
ENSG00000265491.4,RNF115LUSCBosutinibEAG1.1387e-03-0.1457image
ENSG00000265491.4,RNF115MESOAMG.706EAG1.1307e-02-0.2819image
chr1:145745194-145746213:-MESOAMG.706EER1.1333e-02-0.2818image
ENSG00000265491.4,RNF115OVBMS.536924EAG5.7581e-05-0.2335image
chr1:145745194-145746213:-OVBMS.536924EER1.6925e-04-0.2187image
chr1:145781950-145783120:-OVAMG.706EER2.1718e-03-0.6442image
ENSG00000265491.4,RNF115PAADBleomycinEAG7.6877e-030.2014image
chr1:145745194-145746213:-PAADBleomycinEER7.7273e-030.2013image
chr1:145745194-145746213:-PCPGFTI.277EER4.4341e-050.3044image
ENSG00000265491.4,RNF115PCPGFTI.277EAG1.1955e-040.2867image
ENSG00000265491.4,RNF115PRADCEP.701EAG5.1377e-06-0.2027image
chr1:145793067-145794160:-PRADBMS.509744EER1.7491e-03-0.4022image
chr1:145745194-145746213:-PRADCEP.701EER1.7864e-05-0.1909image
ENSG00000265491.4,RNF115READMetforminEAG6.5626e-04-0.3452image
chr1:145745194-145746213:-READMetforminEER6.5626e-04-0.3452image
chr1:145745194-145746213:-SARCA.770041EER2.2791e-05-0.2629image
ENSG00000265491.4,RNF115SARCA.770041EAG1.4997e-06-0.2965image
chr1:145745194-145746213:-SKCMAZD6244EER5.5306e-06-0.2083image
ENSG00000265491.4,RNF115SKCMAZD6244EAG5.6071e-06-0.2081image
chr1:145793067-145794160:-SKCMDocetaxelEER1.0730e-03-0.6373image
chr1:145793067-145794160:-STADATRAEER2.7334e-030.2015image
ENSG00000265491.4,RNF115STADAZ628EAG1.1508e-04-0.2008image
chr1:145745194-145746213:-STADCGP.60474EER1.2131e-04-0.2006image
chr1:145774398-145776802:-STADAICAREER1.7993e-020.1824image
chr1:145781950-145783120:-STADAICAREER7.1344e-030.2518image
ENSG00000265491.4,RNF115TGCTBryostatin.1EAG5.0196e-03-0.2272image
chr1:145745194-145746213:-TGCTBryostatin.1EER4.7029e-03-0.2289image
chr1:145745194-145746213:-THCAAZD6482EER2.0023e-070.2300image
ENSG00000265491.4,RNF115THCAAZD6482EAG4.0375e-050.1822image
chr1:145745194-145746213:-THYMEtoposideEER8.0013e-050.3655image
ENSG00000265491.4,RNF115THYMAZD6244EAG3.9142e-09-0.5209image
ENSG00000265491.4,RNF115UCECDMOGEAG3.1141e-100.4576image
chr1:145745194-145746213:-UCECJNK.9LEER1.7218e-090.4460image
ENSG00000265491.4,RNF115UCSABT.888EAG1.7419e-04-0.4811image
chr1:145745194-145746213:-UCSABT.888EER1.5170e-04-0.4850image
chr1:145745194-145746213:-UVMEmbelinEER3.6557e-040.3959image
ENSG00000265491.4,RNF115UVMEmbelinEAG3.6557e-040.3959image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType